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Summary
Although 190% of patients with osteogenesis imperfecta
(OI) have been estimated to have mutations in the
COL1A1 and COL1A2 genes for type I procollagen,
mutations have been difficult to detect in all patients
with the mildest forms of the disease (i.e., type I). In this
study, we first searched for mutations in type I procol-
lagen by analyses of protein and mRNA in fibroblasts
from 10 patients with mild OI; no evidence of amutation
was found in 2 of the patients by the protein analyses,
and no evidence of a mutation was found in 5 of the
patients by the RNA analyses. We then searched for
mutations in the original 10 patients and in 5 additional
patients with mild OI, by analysis of genomic DNA. To
assay the genomic DNA, we established a consensus se-
quence for the first 12 kb of the COL1A1 gene and for
30 kb of new sequences of the 38-kb COL1A2 gene.
The sequences were then used to develop primers for
PCR for the 103 exons and exon boundaries of the two
genes. The PCR products were first scanned for heter-
oduplexes by conformation-sensitive gel electrophoresis,
and then products containing heteroduplexes were se-
quenced. The results detected disease-causing mutations
in 13 of the 15 patients and detected two additional
probable disease-causing mutations in the remaining 2
patients. Analysis of the data developed in this study
and elsewhere revealed common sequences for muta-
tions causing null alleles.
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Introduction
Osteogenesis imperfecta (OI) is a heritable disorder that
produces varying degrees of bone fragility associated
with defects in several other tissues rich in type I col-
lagen. Almost 200 mutations in the two genes for type
I procollagen (COL1A1 and COL1A2) have been de-
tected in probands with OI (Prockop 1990; Byers 1993;
Prockop and Kivirikko 1995; Kuivaniemi et al. 1997).
The most severe variants of the disease (OI types II–IV)
are caused primarily by single-base substitutions that
convert a codon for an obligate glycine in the triple helix
of the protein to a codon for an amino acid with a
bulkier side chain that distorts the conformation of the
triple helix. Most of the mutations in the mildest variant
(OI type I) cause decreased expression of proa1(I) chains
because of either premature-termination codons or
RNA-splicing defects in the COL1A1 gene (Willing et
al. 1992, 1994, 1996; Redford-Badwal et al. 1996;
Ko¨rkko¨ et al. 1997). DNA linkage studies have sug-
gested that 190% of probands with OI have a mutation
in either the COL1A1 gene or the COL1A2 gene (Sykes
et al. 1990). However, most unrelated probands have
different mutations, and it has been difficult to define
the mutations in a number of patients with OI type I by
means of previously employed protocols, which have
sought to assay type I procollagen synthesized by either
cultured skin fibroblasts or mRNAs extracted from such
cells.
In the present study, we have developed protocols to
amplify all 103 exons and exon boundaries of both the
COL1A1 gene and the COL1A2 gene by PCR and to
scan for mutations by conformation-sensitive gel elec-
trophoresis (CSGE) (Ganguly et al. 1993; Ganguly and
Prockop 1995). To develop the protocols, it was nec-
essary to complete 90% of the structure of the 38-kb
COL1A2 gene and to resequence extensive regions of
the 18-kb COL1A1 gene. We used the protocols to an-
alyze the COL1A1 and COL1A2 genes in 15 patients
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Table 1
Clinical Summary of OI Type I Phenotypes in Probands
Proband (Code) Year of Birth Fractures
Bone De-
formity/
Short
Staturea Blue Scleraea
Dentinogenesis
Imperfectaa Hearing Lossa Family Historya
1 (421) 1970 Multiple  ND ND  
2 (262 1964 2     
3 (207) 1963 6     
4 (395) 1974 1100     
5 (491) 1990 Multiple   ?  
6 (185) 1974 12     
7 (292) 1967 Multiple  ND   
8 (394) 1952 Multiple     
9 (283) 1956 Multiple  ND ?  
10 (286) 1989 Multiple     
11 (LE) 1963 Multiple   ND  
12 (ROMA) 1980 Multiple     ND
13 (J198) 1970 Multiple    ND 
14 (J210) 1963 Multiple NDa  ND ND 
15 (J218) 1976 Multiple     
a A plus sign () denotes presence; a minus sign () denotes absence; and a plus-or-minus sign () denotes possible presence.
ND  not definitively defined.
with mild OI. Disease-causing mutations were found in
13 of the 15 patients, and two probable disease-causing
mutations were found in the remaining 2 patients. Anal-
ysis of the data, together with analysis of previously
published mutations causing OI, indicate that there are
common sequences for mutations that produce null al-
leles of the COL1A1 gene.
Subjects and Methods
Subjects
All probands presented the typical phenotype of OI
type I. The major clinical manifestations for each of them
are summarized in table 1.
Protein Analysis
A skin biopsy was obtained from probands 1–10, and
fibroblast cultures were established under standard con-
ditions. Cells were seeded at 35,000 cells/cm2. Labeling
of the fibroblasts and purification of the collagen mol-
ecules were performed as reported elsewhere (Nuytinck
et al., in press). In brief, for labeling of the cells, Basal
Medium Eagle (Life Technologies) supplemented with 1
mCi 14C proline/ml, 5% dialyzed FCS, 0.05 mg bAPN/
ml, and 0.025 mg ascorbic acid/liter was added. After
20 h, the medium was removed and supplemented with
proteinase inhibitors (0.1 mg phenylmethyl sulfonyl
flouride/ml, 0.1 mg N-ethylmaleimide/ml, and 2 mM
EDTA pH 7.5). The cell layer was trypsinized, and the
cells were collected by centrifugation and were lysed in
0.5% Triton X-100 in 0.5 M acetic acid. The super-
natant was used for collagen analysis.
Collagen samples were isolated from the medium by
alcohol precipitation and were redissolved in 0.5 M ace-
tic acid. For the conversion of procollagen to collagen,
the samples were digested with 50 mg pepsin/ml (Boeh-
ringer) for 4 h at 15C. The digestion was stopped by
the addition of 0.5 mg pepstatin/ml (Boehringer). SDS-
electrophoresis was performed by the Laemmli (1975)
system, with 3% stacking and 5% separation gel. Prior
to being loaded, the samples were lyophilized, redis-
solved in sample buffer (Tris-HCl pH 6.8, 2 M urea,
and 0.04% bromophenol blue), and denatured for 20
min at 55C. Electrophoresis was performed at 8C over-
night (3.5 V/cm). The gels were processed for fluorog-
raphy by use of 20% 2.5-diphenyloxazole in 100% ace-
tic acid and then were dried and exposed to a hyperfilm
MP (Amersham).
Analysis of Polymorphisms in cDNAs and Genomic
DNAs
Total RNA was isolated from cultured skin fibroblasts
by Trizol (Life Technologies). Prior to cDNA synthesis,
RNA samples were treated with RNase-free DNase (Life
Technologies) to avoid genomic DNA contamination in
the reverse transcriptase–PCR experiments. For the con-
version to cDNA, Moloney murine leukemia virus re-
verse transcriptase was used in combination with ran-
dom hexanucleotide primers. For detection of the MnlI
polymorphisms in the COL1A1 gene, the primers and
conditions used were those given by Sokolov et al.
(1991). After enzymatic digestion, the fragments were
evaluated either by agarose electrophoresis or by sepa-
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ration on polyacrylamide gels by automated laser de-
tection (ALF; Pharmacia).
For the detection of the 4-bp insertion polymorphism
in the 3′ end of the COL1A1 gene (Nuytinck et al., in
press), the following primers were used: 5′-CCT TTC
TGC TCC TTT CTC CA (sense primer) and 5′-AGC
AAC ACA GTT ACA CAA GG (antisense primer). Ap-
proximately 500 ng of genomic DNA was amplified un-
der the following conditions: 94C for 1 min, 56C for
1 min, and 72C for 1 min, for 25 cycles. The products
were separated on a 6% polyacrylamide gel by an au-
tomated laser fluorescent DNA sequencer (ALF; Phar-
macia). A fragment of 430 bp (allele A1) and/or a frag-
ment of 434 bp (allele A2) was obtained by use of size
markers for correct fragment-length evaluation.
Defining the Consensus Sequences of the 5′ Half of
the COL1A1 Gene
To define the consensus sequences, genomic DNAs
from eight unrelated probands with OI were used as
separate templates for PCR with primers based on pub-
lished sequences of the COL1A1 gene (Chu et al. 1985;
D’Alessio et al. 1988; Ma¨a¨tta¨ et al. 1991; Westerhausen
et al. 1991). The PCR reactions were performed with a
commercial DNA polymerase (AmpliTaq Gold; Per-
kin-Elmer) in a 40-ml volume, with thermal cycling at
95C for 10 min, for one cycle, followed by 95C for
40 s, 60C for 40 s, and 72C for 50 s, for 35 cycles.
The PCR products ranged in size from 1 kb to 2.5 kb.
Sequences were defined by automated sequencing (ABI
PRISM 377 Sequencer; Perkin-Elmer; and ABI PRISM
Dye Therminator Cycle Sequencing Ready Kit, with
AmpliTaq DNA polymerase, FS; Perkin-Elmer). Prior to
the sequencing, the samples were treated with exonu-
clease I, to degrade the residual PCR primers, and with
shrimp alkaline phosphatase, to dephosphorylate the re-
sidual nucleotides (Hanke and Wink 1994; Werle et al.
1994).
Completing the Structure of the Human COL1A2
Gene
To sequence the 5′ end of the human COL1A2 gene,
a 14-kb fragment spanning introns 1–21 was obtained
from an EcoRI/EcoRI genomic fragment that had pre-
viously been cloned into bacteriophage in the course of
the definition of one mutation that had been shown to
cause OI (Vasan et al. 1991). The fragment was broken
randomly by sonication, and the fragments were size
separated by gel electrophoresis. The selected fragments
were subcloned into a plasmid (pUC18), and 60 clones
were isolated. Plasmid DNA from 13 color-selected col-
onies indicated that the inserts ranged in size from 500
to 4,000 bp. Approximately 90% of the sequences were
recovered by shotgun sequencing of the clones. The re-
maining gaps were closed by sequencing the original
bacteriophage clone containing the 14-kb genomic frag-
ment, by manual or automated procedures.
To complete the structure of the COL1A2 gene, a
genomic P1 clone containing the complete human gene
was obtained by PCR screening of human P1 library
(Genome Systems). Screening was done by PCR ampli-
fication using primers designed on the basis of the pub-
lished human cDNA sequences (de Wet et al. 1987; Kui-
vaniemi et al. 1988). The PCR primers were C1PF1
(5′-GTA CAT TTC CTA GAG AAC TTG) and C1PR1
(5′-CTA CTC TCA GCC CAG GAG GTC CTG), cor-
responding to sequences in intron 19 and exon 21/intron
21. Three positive clones were obtained: DMPC-HFF1
1250-E2, GS control 7403; DMPC-HFF1 1365-B1, GS
control 7404; and DMPC-HFF1 1473-F6, GC control
7405. Because P1 clone 7407 was found to contain the
entire coding sequences of the human COL1A2 gene,
the clone was selected for detailed characterization of
the gene.
To increase the yield of DNA, P1 clone 7407 was
transferred from Escherichia coli strain NS3529 to E.
coli strain NS3516 via transduction, as suggested by
Genome Systems. The P1 plasmid DNA was isolated by
the method of Birnboim and Doly (1979), with modi-
fications suggested by Genome Systems. The isolated
DNA was dissolved in water and was further purified,
by spot dialysis with a membrane (VSWP 02500; Mil-
lipore), against water.
Nucleotide sequencing was performed by cycle se-
quencing of the P1 clone (dsDNA Cycle Sequencing Sys-
tem; Life Technologies; and Cycle Sequencing Kit; Phar-
macia Biotech). Sequencing primers for the COL1A2
gene were designed on the basis of published cDNA and
genomic sequences (Bernard et al. 1983; de Wet et al.
1987; Kuivaniemi et al. 1988). Additional primers were
designed on the basis of sequences obtained during the
study. The 5′ end of the primer was labeled with T4
polynucleotide kinase (U.S. Biochemical) and [g-33P]ATP
(DuPont NEN). For cycle sequencing, 0.5–2.0 mg of P1
DNA was used as template, and thermal cycling was
performed with a commercial instrument (either
GeneAmp 9600; Perkin Elmer; or PTC 225 DNA Engine
Tetrad; MJ-Research). Some of the nucleotide sequences
were obtained by the Terminator Cycle Sequencing
Ready Reaction kit and ABI PRISM 377 DNA Sequencer
(Perkin-Elmer). The data were analyzed by means of the
Wisconsin Sequence Analysis Package versions 8.0 and
8.1 UNIX (Genetics Computer Group) and the Editseq
program from the Lasergene software package
(DNAStar).
Mutation Analysis
Genomic DNA was extracted from blood samples or
from cultured skin fibroblasts. The exons and the flank-
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ing sequences of the 51 exons of the COL1A1 gene and
the 52 exons of the COL1A2 gene were amplified by a
series of specific primers (table 2). Genomic DNA was
amplified in a 40-ml volume, by thermal cycling at 95C
for 10 min, for one cycle, followed by 95C for 40 s,
60C for 40 s, and 72C for 50 s, for 35 cycles. This
was followed by heteroduplex formation steps: 95C for
5 min and 68C for 30 min. CSGE analysis was per-
formed as described elsewhere, with the precaution that
the taurine buffer was not autoclaved (Ganguly et al.
1993; Ganguly and Prockop 1995). The gels were ex-
amined with a hand-held UV illuminator (short wave),
to identify regions containing bands of homoduplexes
and heteroduplexes. Appropriate regions were cut from
the gels, transferred to a filter paper, and analyzed fur-
ther in a UV-image analyzer with a CCD camera (DOC-
ITTM Gel Documentation System; UVP). The image from
the monitor was recorded by a thermal printer. PCR
products containing heteroduplexes were sequenced ei-
ther manually (Sequenase PCR Product Sequencing Kit;
USB) or by automated instrument (ABI PRISM 377 Se-
quencer; Perkin-Elmer; and ABI PRISM Dye Thermi-
nator Cycle Sequencing Ready Kit with AmpliTaq DNA
polymerase, FS; Perkin-Elmer) after treatment with ex-
onuclease I and shrimp alkaline phosphatase (Hanke and
Wink 1994; Werle et al. 1994). PCR products that con-
tained deletions in one allele were purified from agarose
(QIAEX II Gel Extraction Kit; Qiagen). Approximately
60 ng of purified product was cloned into a plasmid
(pT7 Blue T-Vector Kit; Novagen) and was sequenced.
Results
Detection of Mutations by Assays of Protein and
mRNAs
In initial experiments in the present study, fibroblasts
from 10 probands with type I OI were assayed for the
ratio of newly synthesized chains of type I and type III
procollagen. Also, the fibroblasts were assayed for the
presence of polymorphic markers in mRNA that reflect
expression of both alleles of the COL1A1 gene. As is
shown in table 3, a reduced ratio of newly synthesized
type I to type III procollagen was found in 7 of the 10
probands, and a slight reduction was seen in an 8th
proband (probands 1–8); the ratio was normal in fibro-
blasts from 2 of the probands (probands 9 and 10). An
assay for a polymorphic base in the mRNA indicated
that one COL1A1 allele either was not expressed or was
expressed at a reduced level in fibroblasts from five pro-
bands (probands 1–4 and 9), including one in whom the
protein assays were normal (proband 9). The mRNA
assay indicated that both alleles were expressed in one
proband with a decreased ratio of type I to type III
collagen (proband 8). The mRNA assays for four pro-
bands were noninformative.
Sequences of the COL1A1 and COL1A2 Genes
To develop PCR primers for analysis of the COL1A1
and COL1A2 genes, new sequences were defined. In the
case of the COL1A1 gene, several groups contributed
to the complete structure of the gene (Chu et al. 1985;
D’Alessio et al. 1988; Ma¨a¨tta¨ et al. 1991; Westerhausen
et al. 1991). However, in the present study, our attempts
to develop PCR primers based on published sequences
of the 5′ half of the COL1A1 gene were largely unsuc-
cessful; apparently the published sequences were not
from the most frequent alleles of the gene. Therefore,
about 12 kb of the COL1A1 gene were re-sequenced
from genomic DNA of 8 individual probands. A new
consensus sequence was developed that in some regions
differed considerably from the previously published se-
quences. For example, comparison of 3.4 kb of se-
quences from introns 6–24 indicated that 9.6% of the
nucleotides differed. Except for 13 single-base poly-
morphisms in the introns, the same consensus sequence
was found in 16 alleles from eight unrelated individuals.
The revised consensus sequence of the complete 18-kb
COL1A1 gene have been submitted to GenBank (acces-
sion number AF017178).
In the case of the COL1A2 gene, previous publications
provided the complete cDNA of ∼5 kb coding for the
proa2(I) chain (Bernard et al. 1983; de Wet et al. 1987;
Kuivaniemi et al. 1988), ∼4 kb of genomic sequences
that included ∼400 bp of the promoter and 5′ UTR, and
3.5 kb of introns (Myers et al. 1983; Dickson et al. 1984,
1985; Kuivaniemi et al. 1988; Tromp and Prockop 1988;
Sherwood et al. 1990; Ganguly et al. 1991; Vasan et al.
1991). In the present study, we sequenced 130 kb to
provide the complete sequence of the 38-kb gene. Ap-
proximately 11 kb of new sequences from the 5′ end of
the gene were obtained from a 14-kb EcoRI/EcoRI ge-
nomic fragment (Vasan et al. 1991). An additional 19
kb of sequences of the COL1A2 gene were obtained
from P1 clone 7407. The results defined all the intron
sizes and sequences (fig. 1). The sequences of the
COL1A2 gene have been submitted to GenBank (acces-
sion number AF004877).
The intron sizes of the human COL1A2 gene were
approximately the same as the previously defined introns
of the corresponding 30-kb gene from chick (Boedtker
et al. 1985). As noted elsewhere, there were major dif-
ferences between the intron sizes of the human and chick
COL2A1 genes (Ala-Kokko et al. 1995).
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Table 2
Oligonucleotide Primers for PCR Amplification of Promoter Regions, 103 Exons, and Flanking Sequences and Polyadenylation Signals of the
COL1A1 And COL1A2 Genes
COL1A1 COL1A2
Region Sequence Position
Size
(bp) Sequence Position
Size
(bp)
Promoter:
5′ atcctgaggacccagctgcac 387 344 gccacgtcccttcccccattc 312 340
3′ gttagcgtccgctcatgcgtg 44 aagtccgcgtatccacaaagctgagcat 28
Exon:
1:
5′ gacgggagtttctcctcggggtc 115 321 agttggaggtactggccacgactg 108 315
3′ gagtctccggatcatccacgtc 103 gcgttttcccacatgcctgag 137
2:
5′ gctgatgaggagcaggcgag 161 333 tgctgatccctgccatacttttgac 189 280
atccaagtgtgcctcttagac 90 tcttcccttccaagagaagacatc 80
3′ gtttgctaatgctgctcccgtc 108
3:
5′ gctggaggcctctgccgacgggagcagc 71 240 gtgaaggtatatttgtatactacac 97 279
3′ ggcctcgggggccagtgtctc 133 tgttatcttaaacatcaaagctac 167
4:
5′ gcctctgccgacgggagcagc 201 372 cattgtagttacatcagtcttacc 112 294
3′ aggctgtccagggatgccatc 135 gcttcttctgcagtgcattacctg 146
5:
5′ acctggcctcttgtttcttctc 162 386 tccaccctacttgcacatagaaagg 110 385
3′ ctgtaggattcttgcaacttttct 122 gacaagggctcacaaagagaatggg 182
6:
5′ cacaccaggaagtgcatgatgtcag 99 261 tcggccaagtttttgacgtacagct 208 338
3′ ctcccaagctgtctataccagccgc 90 tggcgtggtaaaatgtgacataaaa 76
7:
5′ atacgcggctggtatagacag 166 300 gggaggaataaaaactatggaatc 125 316
3′ tctctgagcatctctcctgccctca 89 gaccagcttcaccaggctcac 146
8:
5′ tggagggaagactgggatgag 111 247 gtactgaaagcttgtaatgcctc 88 223
3′ aagacccaggcctgggagttcttct 82 ggagacccatcatttcactaagg 81
9:
5′ cccctggtgagcctggcgag 194 347 tgaacctggtcaaactgtgagtac 109 273
3′ ctgagtatcgttcccaaatgtg 97 tgtcaggcatattcagcttttggca 110
10:
5′ ctggggccccccaaacctgacctgc 120 262 accaagattcccccatttgtgctga 70 344
3′ ggccattagaacacactcactg 88 gttgcttatggtatgcttgctgtc 220
11:
5′ ctgaacctgggcttcactgcac 98 292 tttgtcgctctgtgcttagagg 143 321
3′ gatgtccactctctggcccttg 140 cttccctttggcaaactccagggat 124
12:
5′ caaagggatggcggtgatgac 111 253 gctgggacctggaacactggacttc 145 260
3′ ctgtagatcagagaataatgag 88 tggaggtcatggggaatttcaatca 61
13:
5′ gtaagaggctgtctgaacatc 88 228 gaacctggatatgtggtactatctg 212 361
3′ gtcagatgagatgggagacagc 95 gaatacaatgctgaaggatacagtg 104
(continued)
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Table 2 (continued)
COL1A1 COL1A2
Region Sequence Position
Size
(bp) Sequence Position
Size
(bp)
14:
5′ ggtgagtgtgcccagttccag 117 263 cttgtacaggttggaaactgaac 94 258
3′ cgttaagtccactgagcactg 92 ccacgggcaccctaagaaga 110
15:
5′ gatccctgagctctggaaggggctc 83 279 ccgtgggcttcctggtgagag 148 298
3′ gagatggcagctgcaagtcac 145 tggtaaagtgtctgaaatgatgc 105
16:
5′ gggcgaggttatgttggtctg 102 229 caccctggataccatgaatgtc 187 318
3′ tttggggaacagggagacatgaacc 73 ctgcaaacacagttccaatctttca 77
17:
5′ ctgatcattgctctcctgtccctgt 103 320 cagtagccaagatggcagaatc 191 462
3′ accaggctgtccatcagcac 118 ccagtaaggccgtttgctccag 172
18:
5′ taagtgtccccgactcagtgtc 88 220 cgttggacctcctgtaagtag 156 306
3′ agccagggcgtgacgtaggag 87 aaaatgcagtgtggtccattagg 105
19:
5′ aagtatcctgccaggcttcag 101 319 taatgtgtgctgcctctacagc 64 330
3′ gaagaggatgagctgagagtc 119 catatagcagacgggagtgtac 167
20:
5′ caagggtaacagcgtgagtac 144 348 cttgagcttctctttaccttgac 106 325
3′ tgaggctgggcctccagtgtc 150 caccactgggaccaggaggac 165
21:
5′ ggctctgaggctggcacaggatg 65 292 cgtaagtagctctatcatcac 126 363
3′ ggaaaccacggctaccaggtc 119 aaggcagatggaaagcagatg 129
22:
5′ ccggaccccctggcgagcgtg 114 278 gggttgggtgaagtgttttggcttg 135 268
3′ cacaggaacagttagggtctc 110 gaggatgctaaagctaatgacac 79
23:
5′ cccaaggtaacctctccttgc 131 309 gctgtctatcacttacttcctag 109 268
3′ gatccggaacgcctcatcccaagac 79 tcaaaaatgcaactgtcagcaagac 136
24:
5′ gtcttgggatgaggcgttccggatc 110 283 aaaaagtcgggggaaaaggtgcctt 101 349
3′ gtccggggcgaccatcttgac 119 tctcccctgctctgctttcagtcct 194
25:
5′ gccctggcagccctggtcctg 129 368 tttcatccgtggcagcatcataagc 81 276
3′ tagggaggctgaggtccagaaagtg 140 ctgagactggactgattcgcag 96
26:
5′ agggcccagcaagaagcacctgc 160 309 tggagctgcatggtgatggatc 165 298
3′ gctgaggaccgtggcctctagc 95 tatcagatggtgtaaaaaaaaaagtgtggttcttagatg 79
27:
5′ cctgcaggaggggtgctagag 83 239 gctttcgtgggaacccacaatgagt 139 315
3′ cacagagagaacactacagtcac 100 tagcaacgtatgtcaccactg 122
(continued)
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Table 2 (continued)
COL1A1 COL1A2
Region Sequence Position
Size
(bp) Sequence Position
Size
(bp)
28:
5′ ctgctgtgagtgtccctgatg 108 247 tggccatctccattttcagtc 92 257
3′ ggagggaaggtttagaatctg 85 tgcttcagtcctgaaatcatgt 111
29:
5′ ggtgaggcctcatggctgtc 112 251 gagctgtaaatcaccataccgtac 115 333
3′ tggctgtctgattagctaggaggcgg 85 tggctcattctctccatcagcac 164
30:
5′ gggttcctctctaatcacggccagac 110 246 tgcactcatgtagatactgccaggt 121 264
3′ agaagggaaggacagggcatgtgaag 91 gacttgttgcagggtcatcagtggc 100
31:
5′ cctctggagcaagagtaagtag 107 318 aaaccagggctcggaagctacacaa 102 359
3′ accccacaccctatctccatg 112 ggtccactggaatcggattgctgtt 158
32:
5′ tttctcaaggcttgtcgttggccttg 120 291 tctccctcctttcaatagcccagcc 152 336
3′ gattcaaaggaggcagagatgggagc 63 gtgaaaacttgggcatccttgtgca 75
33:
5′ cctctcaggaaacccagacacaagcaa 87 318 gaatggtaaggaatcgagacattgc 148 276
3′ aatttggaaaattctcaattcaacataaaaaaaaatccaagtacgaag 74
34:
5′ ggagtaccctccttctgagagtggc 198 330
3′ gttcccaggttgacagctcaga 123 attgctggggctctttgggactagg 78
35:
5′ gtcctgccaaactgagctgtc 129 327 actctgtgagatgtgcgtcag 137 320
3′ attggagagatgcgtctgacaggagg 144 gttggggccagcaggaccgac 140
36:
5′ ccctgtctgtgccttcaccccttgc 97 249 gaagccctgtaagtaagaacctg 112 246
3′ cttctcccctgaggatggctgac 98 gttacagctctggtattccgac 80
37:
5′ tgcctccattactgctcctcc 81 276 gatttgctggtccggctgtgag 113 348
3′ tgtaggagagcacagacgcatcaagc 87 cttccgttattttccatcttctatc 127
38:
5′ tgagtggcttggccctctgtg 97 240 tgcgggaatgatccacttgaagaaa 85 283
3′ agagggagaacagccaactcatccg 99 tcggaattgctctgaatagaatgaa 144
39:
5′ gagtatcacccgcctctctgttgagc 124 259 gaaattcccatcttacccaaattcttg 70 263
3′ tcagtcagccccaccatccttctg 81 gaaaagctgacttcagaccaggag 139
40:
5′ gtgggggctgccagaaggatg 94 337 cataaaggaagacaggagttgc 192 447
3′ tgaggtgccagacagcagcacag 81 catcaacaaatagatgccacttg 93
41:
5′ agtgccagctcagatctctgcagctc 98 309 ctcacaatcttcaagccaacctgtg 75 258
3′ gtccgctggagtcatctctac 103 tctgtcacatttgaagtggcagctt 75
(continued)
Ko¨rkko¨ et al.: Analysis of the COL1A1 and COL1A2 Genes 105
Table 2 (continued)
COL1A1 COL1A2
Region Sequence Position
Size
(bp) Sequence Position
Size
(bp)
42:
5′ gagaacagatttggtagagatgac 84 329 ggaggggaaggttagcattccatcg 64 351
3′ caggggaaccttcggcaccag 135 aaagcccattctttggcctaagcaa 179
43:
5′ cccatgccagtaccctcagcatggc 90 242 agggttcgttactgagcactg 110 323
3′ gggagagcaggggaatatgggtcag 98 ccacggggccatgaggaccag 159
44:
5′ gcaacactccatgaccacagc 96 304 atggtcaacccggacacaag 106 331
3′ cctgcctgggtgaagtccgac 100 caacttagctaggcccaagatac 117
45:
5′ ggagagagagatccagcagagggga 94 246 caacccagattgatgctaagcttc 288 480
3′ gggacaaactgtcaggcggaagttc 98 gtatcaattctcagcatggactg 138
46:
5′ catgccttcagaactctacag 90 297 gcagattaccagcagaggtgagagc 145 320
3′ ggggaaagaatgactatccag 99 tgaaaatccttctgagctgaaggcc 67
47:
5′ gttgcccacactgcccttgtc 92 249 tcccattgaatttggaaaaaaaaaaaatatgtctcttgac 81 257
3′ aacccttctccagagaggcaaaggg 103 gacaccaggtacatgtgagctg 114
48:
5′ ccgtggggccagagccagcag 102 299 caagagaagacagttcatctctg 115 326
3′ gcacagagagggaagagagtgggga 89 tggggctaactttaatgggttgtc 103
49:
5′ gctggtcctgttgtatgtagc 103 475 gaacatgcttccgtgtgaagctc 102 535
3′ ccagcaccatatggtaggggcacat 89 agggaaatgaggttgggtgctggtt 177
50:
5′ ccagggtccccatgcccatatgtgc 87 344 tgttacttatgagagtcagtatctttc 98 459
3′ catgtcccttctgagcactgggcta 66 gtccaatcaatccatcttctaatgtg 176
51:
5′ ggaccctggacaggaaggccagcagg 74 399 cccttttcctaagcttggatctgag 132 471
3′ gatggagagagggcactatggc 82 ttaacccccctttagaccccccttg 96
52:
5′ gggctttttggccaggccatagtgcc 84 319 ggacagacatcttcagaatgac 120 401
3′ gagggggttcagtttgggttgcttgtctg 88 ttgcccacaatttaagcaagtag 134
Polyadenylation signal:
A1:
5′ tttttcctttgcattcatctctc 138 303 ccttccatttcttctgcacatctac 91 323
3′ cattgtttcctgtgtcttctgg 440 tgtggatcacactcatgggaaagtg 413
A2:
5′ agagacaacttcccaaagcac 1256 217 gttcataatacaaaggtgctaat 525 273
3′ aggccccttccccatgtctac 1472 gaaacaaagcttctgtggaacc 737
a Exons 33 and 34 were fused for the COL1A1 gene.
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Table 3
Mutations Detected in OI Type I
Proband (Code)
Reduced
Ratio, Pro-
collagen I:
Procollagen
IIIa
Absence
of
COL1A1
Allele in
mRNAb Mutation in COL1A
1 (421)   A3IVS22rG
2 (262)   G12IVS20rA
3 (207)   A2IVS5rG
4 (395)   del T nt 927 (E12)
5 (491)  NI Arg183rstop
6 (185)  NI del T nt 2192 (E31)
7 (292)  NI del G nt 3198 (E43)
8 (394)  0 G1IVS12rA
9 (283) 0  del T nt 2732 (E38)
10 (286) 0 NI Arg42rstop
11 (LE) NA NA ins C nt 1787 (E24)
12 (ROMA) NA NA Arg519rstop
13 (J198) NA NA ins AC nt 1838 (E25)
14 (J210) NA NA G1IVS25rA
15 (J218) NA NA G1IVS18rA
a A plus sign () denotes presence; a minus sign () denotes absence;
and a plus-or-minus sign () denotes possible presence. NA  not
assayed.
b A plus sign () denotes presence. NI  noninformative assay
(because proband was homozygous for polymorphism); and NA 
not assayed.
Figure 1 Schematic representation of the genomic organization of the human COL1A2 gene. The exons and introns are drawn to scale;
the exact sizes are given for the introns.
Primers for PCR Amplification of the Exons and Exon
Boundaries
The sequences of the human COL1A2 gene that have
been defined in the present study, together with the pre-
viously published sequences of both the COL1A1 gene
and the COL1A2 gene, were used to design primers for
amplification of each of the 103 exons and of x80 bp
of the 5′ and 3′ flanking sequences (table 2). Conditions
for PCR amplification were optimized so that each PCR
product gave a discrete band detectable by agarose gel
electrophoresis and by PAGE. In addition, the primers
were designed so that the PCR products were not 1500
bp, so that the presence of single-base substitutions could
be detected by heteroduplex analysis using CSGE (Gan-
guly and Prockop 1995; J. Ko¨rkko¨, S. Annunen, D. J.
Prockop, and L. Ala-Kokko, unpublished data).
Detection of Mutations in OI Type I by PCR and CSGE
Scanning
The new protocols were used to search for mutations
in the initial 10 probands with type OI and in 5 addi-
tional probands (table 1). Twenty-five polymorphisms
in the COL1A1 gene and 18 polymorphisms in the
COL1A2 gene were detected with frequencies ranging
between .01 and ∼.5 (not shown). Most of the poly-
morphisms were found within the intron sequences an-
alyzed. In addition, the results detected the presence of
unique heteroduplexes in each of the 15 probands (see
fig. 2). Sequencing of the PCR products that generated
unique heteroduplexes identified 13 mutations. Five of
the mutations were single-base deletions or insertions
(probands 4, 6, 7, 9, and 11; table 1), one mutation was
a 2-bp insertion (proband 13), and three of the muta-
tions were single-base substitutions that converted a co-
Ko¨rkko¨ et al.: Analysis of the COL1A1 and COL1A2 Genes 107
Figure 2 CSGE assays of PCR products for heteroduplexes re-
flecting the presence of single-base changes in the COL1A1 gene. Sam-
ples are from probands described in tables 1 and 2. Dots indicate
homoduplex and heteroduplex bands that are readily visible by UV
illumination of the gels but that are difficult to reproduce by the image
provided by the thermal printer of the UV-image analyzer.
don for arginine to a premature-termination codon (pro-
bands 5, 10, and 12). Four mutations altered consensus
sites of RNA splicing in the first two or last two bases
of an intron (probands 3, 8, 14, and 15). Two additional
changes in the two remaining probands were also likely
to alter RNA splicing, one at position 3 of intron 22
(proband 1) and the other at position 12 of intron 20
(proband 2). Although the bases at these two positions
are not conserved in all introns (Nakai and Sakamoto
1994), the mutations were not found in 100 other
COL1A1 alleles. Also, no other changes were found in
the analysis of all the other PCR products from the
COL1A1 and COL1A2 genes of these two patients. In
addition, the protein data and the mRNA data both
indicated that one COL1A1 allele was not expressed at
a normal level in both probands. Two other observations
supported the conclusion that the single-base change at
position 12 of intron 20 in proband 2 was a disease-
causing mutation. One observation was that the same
change was found in the proband’s affected father and
sister but not in his unaffected brother, and the second
observation was that the single-base change at12 pro-
duced a 3′ consensus sequence for RNA splicing—that
is, it converted a sequence of (Pyr)11CGG to (Pyr)11CAG.
In summary, definitive disease-causing mutations were
found in 13 probands, and probable disease-causing mu-
tations were found in the other 2 probands. As indicated
in table 3, all the mutations detected were in the
COL1A1 gene.
Identification of Common Sequences for Mutations
Causing COL1A1 Null Alleles
Comparison between the data generated in the present
study and those reported for previously defined muta-
tions in OI identified common sequences for null-allele
mutations in the COL1A1 gene (Willing et al. 1994,
1996; Redford-Badwal et al. 1996; Ko¨rkko¨ et al. 1997).
For the sake of comparison, we first considered single-
base substitutions that converted a codon for arginine,
CGA, to a premature-termination codon, TGA. There
were nine mutations that met this criterion (table 4).
All were found in the sequence context of C/GCC CGA
GG/T in the COL1A1 gene. They were found in five of
the six such sequences in the wild-type COL1A1 gene.
In contrast, no such mutations have yet been reported
that convert codon of CGA for arginine in seven other
sequence contexts of the COL1A1 gene—that is, in
which the CGA is not preceded by G/CCC.
A second category of mutations were mutations that
created frameshifts and premature-termination codons
because of single-base deletions or insertions. A total of
14 such mutations have been reported in the COL1A1
gene (table 5). Nine of the mutations were in the se-
quence context of CCC CCT. Only 5 of these 14 mu-
tations were found in other sequences. In the COL2A1
gene, six such mutations were reported, and two are in
the sequence context of CCC CCT (table 5).
Discussion
Assays of procollagens and mRNAs in cultured skin
fibroblasts have been useful in the definition of muta-
tions that cause OI. However, as illustrated here, the
assays do not detect all mutations, particularly in OI
type I. Also, the assays require biopsies of skin and cul-
ture of fibroblasts for x3 wk. For these reasons, we
developed protocols for PCR amplification of the exon
and exon boundaries of all 103 exons of the COL1A1
and COL1A2 genes.
To develop PCR-amplification primers directly from
genomic DNA, it was necessary to perform extensive
resequencing of the 5′ half of the COL1A1 gene and to
sequence 30 kb of the 38-kb COL1A2 gene. Comparison
between our data for the human COL1A2 gene and
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Table 4
Common Sequences in COL1A1 for Mutation of CGA Codons to Premature-Translation-Termination Codons
Sequence Context No. of Mutations Exon Reported Amino Acid Number Reference(s)
CCC CGA GG 1 9 42 Present study
CCC CGA GG 1 17 183 Present study
GCC CGA GG 2 19 237 Redford Badwal et al. (1996);
Willing et al. (1996)
CCC CGA GG 2 31 519 Willing et al. (1996); present
study
CCC CGA gt 3 47 963 Willing et al. (1994); Ko¨rkko¨
et al. (1997)
GAC CGA GA 0 2
CCC CGA GG 0 4
GGC CGA GA 0 5
GCT CGA GG 0 11
AAG CGA GG 0 21
GAG CGA GG 0 26
GGC CGA GT 0 39
GGA CGA GA 0 43
Table 5
Null-Allele Mutations Produced by Single-Nucleotide Insertions or
Deletions
GENE
NO. OF CCC
CCT
SEQUENCES
REPORTED SINGLE-BASE INSER-
TIONS OR DELETIONS
Total In CCC CCT Sequence
COL1A1 30 14a 9
COL1A2 6 0 0
COL2A1 16 6b 2
COL3A1 7 0 0
a Source: Dalgleish (1997); present study.
b Source: Ahmad et al. (1995); Brown et al. (1995); Kuivaniemi et
al. (1997); A. De Paepe (unpublished data).
previously reported data on the chick COL1A2 gene
(Boedtker et al. 1985) indicate that the intron sizes are
conserved. In contrast, the intron sizes of the COL2A1
gene are not conserved (Ala-Kokko et al. 1995). The
primers for PCR amplification of the exons were devel-
oped so that the PCR products could be scanned, by
CSGE, for single-base differences and other mutations
(Ganguly et al. 1993; Ganguly and Prockop 1995). The
availability of the scanning technique greatly reduced
the amount of DNA sequencing necessary to search for
mutations in the genes of patients with OI.
With the new protocols, definitive disease-causing mu-
tations were found in 13 probands with type I OI, in-
cluding 2 probands in whom protein assays were neg-
ative and 1 proband in whom the RNA assay was not
informative. In addition, probable disease-causing mu-
tations were found in the remaining 2 probands.
One of the initial hypotheses informing the present
study was that probands in whom no mutations were
found in the COL1A1 gene were likely to have mutations
in the COL1A2 gene. However, no mutations in the
COL1A2 gene were found. Therefore, mutations in the
COL1A2 gene appear to be a rare cause of OI type I,
even though mutations in the gene can cause some severe
variants of OI (see Kuivaniemi et al. 1997). Individuals
and mice heterozygous for nonfunctional proa2(I)
chains probably have decreased bone density (Dickson
et al. 1984; Chipman et al. 1993; Saban and King 1996).
Therefore, individuals with nonfunctional COL1A2
genes may have phenotypes that are milder than OI type
I and that overlap with that of osteoporosis.
As suggested by previous reports (see Byers 1993; Kui-
vaniemi et al. 1997), most mutations found in patients
with OI type I are mutations that introduce either pre-
mature-termination codons for translation or aberrant
RNA splicing and that thereby reduce the expression of
the COL1A1 gene. Analysis of such mutations detected
in the present study and reported previously indicates
that they tend to occur in common sequence contexts.
Of a total of nine mutations that converted the arginine
codon CGA to the premature-termination codon TGA,
all were found in the sequence context of G/CCC CGA
GG/T of the COL1A1 gene (Willing et al. 1994, 1996;
Redford-Badwal et al. 1996; Ko¨rkko¨ et al. 1997). None
were found in seven CGA codons for arginine in other
sequence contexts of the COL1A1 gene. Therefore, the
mutability of the CpG sequence (see Ollila et al. 1996;
Ko¨rkko¨ et al. 1997) is apparently enhanced by the con-
text. Ollila et al. (1996) have noted that CpG is more
mutable in the context of YYCGRR—and especially in
the context of YYCGRY—than in other contexts. The
results of the present study agree with this suggestion.
As noted here, the COL1A1 gene has six G/CCC CGA
GG/T sequences, whereas the COL1A2 has none. A sim-
ilar analysis has indicated that single-base insertions or
deletions in collagen genes are frequently in the context
of CCC CCT. As noted by Jego et al. (1993), such mu-
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tations are likely to occur in duplicated sequences. In
the case of collagens, the sequence CCC CCT, coding
for Pro-Pro or Pro-Hyp, is a common sequence in the
COL1A1 gene, and 9 of the 14 reported single-base in-
sertions or deletions in the COL1A1 gene are in such a
sequence. As is seen in table 5, such sequences are less
common in the COL1A2, COL2A1, and COL3A1
genes, but two of the six null alleles reported in the
COL2A1 gene are in the sequences.
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